Targeting inflammation to boldly transform the lives of patients with severe neurological diseases
Mentions in press and media 2
| Date | Title | Description |
| 04.09.2024 | Egret Therapeutics Announces Appointment of Ron Cohen, M.D. to its Board of Directors | Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation post acute ischemic injury NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Egret Therapeutics today ann... |
| 22.02.2022 | Egret Therapeutics Completes Pre-A Financing Round | Egret Therapeutics, a New York-based clinical-stage biotherapeutics company, raised an undisclosed amount in Pre-A funding. The round was led by Fascinate Therapeutics with participation from Turret Capital Management. Led by CEO Dr. Daniel... |